"Estrogen (medication)"

contextsGonadotropin-releasing hormone agonist (GnRHa) A long-acting pharmacological analogue of naturally produced gonadotropin-releasing hormone that is prescribed to inhibit production of pituitary gonadotropins (LH and FSH), thereby inhibiting gonadal production of sex steroids (i.e., testosterone or estrogen)Medical transition The process of undergoing medical treatment to align one’s physical experiences

treatment requires close skin monitoring. Pregnancy, menopause, contraceptive use, hormone replacement therapy, and breast cancer treatment drugs result in substantial shifts in hormone levels. Additionally, hormone levels are altered by aromatase inhibitors and anti-estrogen medications. These fluctuations can modulate mechanisms influencing autoimmune skin abnormalities.

. The condition may be linked to increases in oestrogen levels. Such states can occur in pregnancy, menstruation and puberty, and with the use of oestrogen medication. In pregnancy the condition usually occurs in the second month and stops after delivery. Oestrogen is thought to act in several ways, including stimulating parasympathetic activity, increasing acetylcholine levels, inhibiting sympathetic neurons

positive breast cancer may benefit from ovarian function suppression in addition to anti-estrogen medications. While these endocrine manipulations have successfully improved breast cancer outcomes, they may lead to a significant proportion of women experiencing vasomotor symptoms. While not life-threatening, vasomotor symptoms adversely impact quality of life and can result in early treatment

with “physiotherapy” OR “pelvic floor muscle exercises” OR “pessaries” OR “conservative treatments” OR “lifestyle” OR “Hypopressives” OR “breathing” were used. The Boolean term “NOT” was used to exclude studies related to surgery, urinary incontinence, pregnancy or oestrogen. Medical subject headings were used. No limits will be placed on date or location. Studies will be limited to English language only.Types

English Estrogen, Estrogens, estrogens (medication), estrogens, oestrogen products, oestrogens, estrogen products, oestrogen, estrogen substance, estrogenic preparation, Estrogens (product), Agonists, Estrogen Receptor, Receptor Agonists, Estrogen, Estrogen Receptor Agonists, Compounds, Estrogenic, Estrogenic Compounds, Agents, Estrogenic, Estrogenic Agents, Estrogen product Sequential Estrogen Replacement Tamoxifen Third Generation Progestin Transdermal Estrogen Triphasil Vaginal Douche Vaginal Estrogen Yasmin Back Links (pages that link to this page) Continuous Estrogen Replacement Emergency Care in ESRD Vaginal Estrogen Medication Causes of Leg Cramps Hemorrhagic Shock Sequential Estrogen Replacement Medication Causes of Hypertension Subclinical Hyperthyroidism Medication

Transdermal Estrogen Triphasil Vaginal Douche Vaginal Estrogen Yasmin Back Links (pages that link to this page) Estrogen Replacement Menopause Continuous Estrogen Replacement Vaginal Estrogen Medication Categories Transdermal Estrogen Atrophic Vaginitis Search other sites for 'Sequential Estrogen Replacement' NLM Pubmed Google Websites Google Images advertisement * Page Contents... * Indications

failure, and hypertension. No history of parkinsonism or other neurologic disorders was reported. Furthermore, the patient had no prior history of dopamine antagonist or estrogen medication use. At admission, she was fully alert and oriented. A physical examination revealed her muscle tone and strength were normal on both sides; however, she reported transient weakness in the right limbs

in the gallbladder.The risk factors associated with the development of cholesterol gallstones include obesity, a high-calorie diet, clofibrate therapy, gastrointestinal disorders involving major malabsorption of bile acids, cystic fibrosis with pancreatic insufficiency, and female sex and the use of oral contraceptives and other estrogenic medications. Coffee and ascorbic acid have been shown to reduce the risk

in the gallbladder.The risk factors associated with the development of cholesterol gallstones include obesity, a high-calorie diet, clofibrate therapy, gastrointestinal disorders involving major malabsorption of bile acids, cystic fibrosis with pancreatic insufficiency, and female sex and the use of oral contraceptives and other estrogenic medications. Coffee and ascorbic acid have been shown to reduce the risk

English Estrogen, Estrogens, estrogens (medication), estrogens, oestrogen products, oestrogens, estrogen products, oestrogen, estrogen substance, estrogenic preparation, Estrogens (product), Agonists, Estrogen Receptor, Receptor Agonists, Estrogen, Estrogen Receptor Agonists, Compounds, Estrogenic, Estrogenic Compounds, Agents, Estrogenic, Estrogenic Agents, Estrogen product Sequential Estrogen Replacement Tamoxifen Third Generation Progestin Transdermal Estrogen Triphasil Vaginal Douche Vaginal Estrogen Yasmin Back Links (pages that link to this page) Continuous Estrogen Replacement Emergency Care in ESRD Vaginal Estrogen Medication Causes of Leg Cramps Hemorrhagic Shock Sequential Estrogen Replacement Medication Causes of Hypertension Subclinical Hyperthyroidism Medication

Transdermal Estrogen Triphasil Vaginal Douche Vaginal Estrogen Yasmin Back Links (pages that link to this page) Estrogen Replacement Menopause Continuous Estrogen Replacement Vaginal Estrogen Medication Categories Transdermal Estrogen Atrophic Vaginitis Search other sites for 'Sequential Estrogen Replacement' NLM Pubmed Google Websites Google Images advertisement * Page Contents... * Indications

. Subjects with history of prior T use, cancer, chemotherapy, or radiation of the brain, abdomen, or pelvis, current use of hormonal medications (including, but not limited to, metformin, insulin, progestins, or estrogenic medications), current endocrinopathy (including, but not limited to, PCOS, androgen secreting tumor, diabetes, or pituitary, thyroid, or adrenal disease), and renal, hepatic, cardiac

levels are interpreted and used to determine risk. MESA is a prospective cohort consisting of 6814 men and women aged 45 to 84 years recruited from 6 US communities. Nonparametric analyses were performed to determine differences in CRP levels by gender in the entire cohort and after stratifying by use of estrogen medication (n = 944). Stratifying by median body mass index (BMI) and generalized linear

performance, greater weight, greater height loss, smoking, history of arthritis and diabetes, and use of thyroid and estrogen medications were independently related to greater declines in lower extremity performance. Lower extremity performance decreased dramatically with advancing age in older women. Effective management of common diseases, such as arthritis and diabetes, and a healthy lifestyle, including

groups), full colposcopic inspection of the transformation zone was possible in a significantly greater proportion of the oestrogen treated group (70% versus 23%, P less than 0.01). As most diagnostic conizations are currently performed on the basis of unsatisfactory colposcopy, the use of oestrogen medication followed by colposcopic reassessment should permit a reduction in the number of patients

Graves or Hashimoto disease in The Netherlands. Baseline assessment included measurement of serum thyrotropin (TSH), free thyroxine (FT(4)), and thyroid peroxidase (TPO) antibody levels as well as evaluation for the presence and levels of Yersinia enterocolitica antibodies. We also gathered data on family background, smoking habits, use of estrogen medication, pregnancy, and exposure to high levels